<img src="https://ws.zoominfo.com/pixel/eCRg8hzy2qp0kNUl6E1g" width="1" height="1" style="display: none;">

NEWSROOM Press Releases

    254 Results

    Biodesix Closes Series D Financing - July 2011

    Biodesix has closed a $20 million series D financing. The new capital will support ongoing commercialization activities for the company's Veristrat.

    VeriStrat® Outcomes Data in Lung Cancer to be Presented at IASLC/ESMO 2nd European Lung Cancer Conference

    Biodesix today announced that results from the VeriStrat biomarker analysis of a Phase III clinical trial will be presented by David Carbone , M.D., Ph.D.

    Biodesix Announces Issuance of Key Patent for Serum Test that Identifies Lung Cancer Patients Likely to Benefit from Targeted Therapy

    Biodesix announced today that the United States Patent and Trademark Office has awarded to the company patent number 7,736,905.

    Biodesix to Present at 2011 Biotech Showcase

    Biodesix's Paul Beresford will present at the 2011 Biotech Showcase conference taking place January 10–12th at the Parc 55 Wyndham in San Francisco, CA

    VeriStrat® Test Identifies Lung Cancer Patients Benefiting from Combination Therapy

    The intention of the biomarker analysis was to evaluate the ability of VeriStrat, to predict patient outcomes with a combination regimen.

    Biodesix Supports Unique Lung Cancer Research Initiative – CASTLE study enrolls initial subjects

    Biodesix announces the enrollment of initial subjects into CASTLE, the inaugural study of the Addario Lung Cancer Medical Institute.

    Biodesix Selected as a Colorado Company to Watch

    Biodesix Inc. announced today that they are one of the winners of the 2010 Colorado Companies to Watch award, developing valuable products and services.

    Biodesix Receives Certification from NY State

    Biodesix has received the clinical laboratory evaluation program certification from the New York State Department of Health’s Wadsworth Center.

    Biodesix Issued Four Additional U.S. Patents for Blood-based Oncology Tests

    Biodesix announced that the U.S. Patent & Trademark Office has issued four patents for the protection of the company's products and technology.

    Biodesix Completes Series C Financing and Receives Grant

    Biodesix Inc. announced today that the company has raised $7.1 million in new equity financing, led by existing investors.